Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02001753|
Recruitment Status : Completed
First Posted : December 5, 2013
Last Update Posted : April 7, 2014
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Device: CMR||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||88 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Health Services Research|
|Official Title:||Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes|
|Study Start Date :||December 2013|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||February 2014|
Experimental: CMR group
Endothelial function, oxidative stress and inflammation were measured before and after CMR.
Placebo Comparator: Placebo group
The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure". This group is called the non-CMR group or sham CMR group.
No Intervention: health subject group
Healthy subjects (30) will be enrolled as controls at baseline.
- Changes of endothelium-dependent arterial dilation before and after CMR in type 2 diabetes [ Time Frame: 3 days ]The endothelium-dependent arterial dilation was measured at baseline, 1day, 2 day, 3 day after CMR.
- Changes of endothelial progenitor cells before and after CMR in peripheral blood [ Time Frame: 3 days ]The numbers of endothelial progenitor cells was determined at baseline, 1 day, 2 day, 3 day after CMR.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02001753
|Wuhan, Hubei, China, 430070|